



Pulmon

The Journal of Respiratory Sciences

Editorial

Fungal Exacerbations of COPD

Arjun P.

Review Article

Airborne Infection Control in Health Facilities

Rakesh P.S.

Original Articles

Pathogenic Fungi in the Environment Causing Acute Exacerbation of COPD and its Link to Coffee Plantations in Wayanad District of Kerala - A Prospective Study

Ravindran Chetambath

Utility of EBUS - TBNA in Mediastinal Lymphadenopathy in a Tertiary Care Centre

Bala P.

Case Report

Pulmonary Adenocarcinoma Masquerading as ILD

Akhilesh Kunoor

Intralobar Sequestration - A Case Report

Jayaprakash B.

Intrapulmonary Teratoma - Bronchoscopic Visualisation

Kesavan Nair V.

Guidelines for authors

Vol 20, Number 3, (Sep - Dec) 2018

ISSN 0973 - 3809

**OFFICIAL PUBLICATION
OF ACADEMY OF
PULMONARY AND
CRITICAL CARE
MEDICINE**

Contents

Vol 20, Number 3, (Sep - Dec) 2018 ISSN 0973 - 3809

Pulmon

The Journal of Respiratory Sciences

Editorial

- 93 **Fungal Exacerbations of COPD**
Arjun P.

Review Article

- 97 **Airborne Infection Control in Health Facilities**
Rakesh P.S.

Original Articles

- 101 **Pathogenic Fungi in the Environment Causing Acute Exacerbation of COPD and its Link to Coffee Plantations in Wayanad District of Kerala - A Prospective Study**
Ravindran Chetambath
- 110 **Utility of EBUS - TBNA in Mediastinal Lymphadenopathy in a Tertiary Care Centre**
Bala P.

Case Report

- 117 **Pulmonary Adenocarcinoma Masquerading as ILD**
Akhilesh Kunoor
- 121 **Intralobar Sequestration - A Case Report**
Jayaprakash B.
- 125 **Intrapulmonary Teratoma - Bronchoscopic Visualisation**
Kesavan Nair V.

Guidelines for authors

General Information

Pulmon 2018; 20:3 89 - 132

Pulmon

The Journal of Respiratory Sciences

Proprietor

Academy of Pulmonary and Critical Care Medicine
Head office (Ernakulam)

Publication data

3 issues published in a year

Web site : www.apccm.in

Journal office & Correspondence

Editor-in-chief PULMON
Dr. Suraj K.P.
Professor,
Dept. of Pulmonary Medicine
Govt. Medical College,
Kozhikode, Kerala, India - 673008
E mail: drsurajkp@yahoo.com

Advertising and tariff requests

Head Office of Academy of Pulmonary and Critical Care Medicine

Dr. Kurian Oommen
Thottathil
Kavumbhagam PO
Thiruvalla -689102
Ph: 0469 2604796, 9847248015
drkurianoommen@gmail.com

Subscription rates

Personal
Single : Rs. 250
Annual : Rs. 600

Institutional
Single : Rs. 250
Annual : Rs. 600

Contact e-mail ID : drsurajkp@yahoo.com

Instructions for Authors

Instructions for submission of manuscripts are published in the journal. Also available in editorial office

Registration

Registrar of Newspapers of India
RK Puram, New Delhi
Regn. No. M6/6468/2001
ISSN 0973 – 3809

Type setting and Printing

Design Desk, Calicut
Ph : 9061 99 54 63

Pulmon

The Journal of Respiratory Sciences
"Committed to the Care of Lungs"

The Official Publication of the
Academy of Pulmonary and Critical Care Medicine

Advisors

Ravindran P.
Ravindran C.
Sukumaran P.

Associate Editor

Jyothi E
Rajagopal T.P.
Santhosh Kumar P.V.

Editorial Assistants

Anandan PT
Anand M.
Kiran Vishnu Narayanan
Safreena Mohammed
Mohammed Musthafa
Paulo V.A.
Sunny George
Vipin Varkey

Section Editors

Anil Joseph
Arjun P.
Balachandran J.
Jayaprakash. B
Kesavan Nair
Madhu K.
Nasser Yusuf
Nataraja Iyer
Pattabhiraman V. R.
Rajesh V
Rauf C. P.
Ramesh Nair K M
Sanjeev Nair
Shajahan P. S.
Sudheendra Ghosh C.
Venugopal K.P
Venugopal P.
Vivek P.

Editor

Dr. Suraj K.P.
Professor,
Dept. of Pulmonary Medicine
Govt. Medical College,
Kozhikode, Kerala, India - 673008
E mail: drsurajkp@yahoo.com

Editorial Advisory Committee

Abdul Khader A. K.
Anitha Kumari K.
Davis Paul
Dhruv Choudhary
Dinesa Prbhu V
Fathahudheen. A
Govindan K. P.
Jain P. K.
James P.T
Jindhal S. K.
Joshi M.
Khilnani G. C.
Mahashur A.
Mohan Kumar T.
Narasimhan R.
Natarajan A. S.
Rajendra Prasad
Ravindra Mehta
Sandeep Salvi
Vijayan V. K.
Barnes P. J. (Professor of Thoracic Medicine,
National Heart & Lung Institute London, UK)
Ravikrishnan K. P. (Director, Pulmonary & Critical Care
Medicine, William Beaumont Hospital, Royal Oak, Michigan)
Martyn R Patridge (Whipps Cross Hospital, London, UK)
John J. Marini (Regions Hospital, University of Minnesota, USA)
Parameswaran Nair (Mc Master University, Hamilton,
Ontario)

Past editors

Ramesh Chandrababu (late) 1999 to 2005
James P. T. 2005 to 2010
Kumari Indira K.S. 2010 to 2012

Pulmon

The Journal of Respiratory Sciences

President

Dr. Ameer K. A.

President Elect

Dr. Rajagopal T.P.

Secretary

Dr. Davis Paul

Joint Secretary

Dr. Vipin Varkey

Treasurer

Dr. Kurian Oommen

Journal Editor

Dr. K. P. Suraj

Governing Council Members

Dr. B. Jayaprakash

Dr. C. G. Bindu

Dr. Praveen Valsan K.

Dr. Jaymohan Unnithan

Dr. Rennis Davis

Dr. Rekha P.

Dr. Sudheer Kumar

Dr. Anand M.

Dr. Babu Varghese

Dr. Sabir M. C.

Ex Officio Member

Dr. K. M. Ramesh Nair

Dr. P. S. Shajahan

Editorial

Fungal Exacerbations of COPD

Arjun P.

Consultant Pulmonologist
KIMS Hospital
Thiruvananthapuram

Acute exacerbations of COPD (AECOPD) are important events in the natural history of patients with COPD as they are associated with increased rates of hospitalization, readmissions, disease progression and a negative health status.¹ It has also been shown that AECOPD causes an accelerated decline in lung function, leading to death also.

The key symptom of an exacerbation is increased dyspnoea, which is brought about by increased airway inflammation, increased mucous production and air trapping. The other symptoms include increased frequency of cough, wheeze and increased sputum volume & purulence.

COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy. In turn, it is subdivided into 3 categories – mild, moderate and severe.

The true incidence of AECOPD is difficult to assess since 50% of exacerbations are not reported by patients. AECOPD accounts for 2.4% of acute hospitalizations in the UK.² Significantly it also accounts for 50% of the direct costs of COPD treatment.³

The most common aetiologies of AECOPD are viral respiratory infections, bacterial infections and non infective environmental factors like pollution and ambient temperature.

Fungal agents causing an exacerbation of COPD though rare, is not uncommon. Although not mentioned in guidelines as a potential

aetiology for AECOPD, these should be kept in mind especially in geographical areas where fungal spores are present abundantly in the ambient air.

Aspergillus species have been described to cause severe exacerbations of COPD.⁴ It has been reported that *Aspergillus* species were isolated from sputum in 16.6% of patients with severe AE-COPD.⁵ Significantly, a history of AE-COPD in the previous year was reported to be a main risk factor for isolation of *Aspergillus* species in the sputum samples. In the FUNGICOPD study, filamentous fungi and *Aspergillus* species were identified in 49% and 42% of sputum from patients with stable COPD, respectively, and *Aspergillus* cultures in COPD patients correlate with neutrophilic inflammation, suggesting the presence of a host immune response against the *Aspergillus* organisms.⁵

Normal pulmonary defence mechanisms against *Aspergillus*, such as the ingestion of conidia by pulmonary macrophages and killing of hyphae by neutrophils, are usually present and preserved in COPD patients. Structural changes in lung architecture including formation of bullae, predispose to colonization with *Aspergillus fumigatus*. Also, the common use of long-term steroids (including inhaled steroids) increase host susceptibility by reducing oxidative killing of the organism by pulmonary macrophages and increase its linear growth by 30-40%. Finally, comorbid factors such as diabetes, alcoholism and malnutrition may further enhance the risk of developing fungal exacerbations.

In this edition of Pulmon, Ravindran Chetambath et al have examined the role of pathogenic fungi causing exacerbations of COPD, in Wayanad district, renowned for its coffee plantations. They have also attempted to correlate it with the cropping season of coffee, from October to January. This is because of the fact that branches of the coffee plant as well as the berries carry white flakes which are rich in fungi and hence the fungal spore concentration in the environment is likely to be high during this period. A remarkable aspect of this study is that they have taken meticulous efforts to collect and speciate fungi from five different coffee plantations in the district, in addition to working up all the patients for fungal pathogens.

The results of this study are indeed an eye opener. They have observed that there is a high prevalence of fungal isolation in their cohort of COPD patients with severe AECOPD requiring hospitalization. Diabetes mellitus, expectedly, has been found to be an independent risk factor for fungal isolation. Fungal isolation has been found to be associated with longer duration of hospital stay and an increase in death rate. A large number of pathogenic fungi were isolated including *Aspergillus fumigatus* from samples collected from coffee plants and berries during this period. *Aspergillus fumigatus*

was the most common fungus to be isolated from patients with AECOPD (16.3%).

This brings into focus the role of biomarkers in diagnosis of AECOPD. Traditionally, C Reactive protein (CRP) has been used to differentiate bacterial from viral exacerbations of COPD. Would fungal biomarkers have a role in future? This is particularly important since fungal exacerbations are severe in nature and are associated with prolonged hospitalisation and even increased mortality. There is some evidence coming up now that elevated levels of serum *Aspergillus* galactomannan is associated with severe AECOPD.⁶ These findings suggest that serum *Aspergillus*-galactomannan antigen is a novel surrogate marker and could potentially be used to evaluate the risk of severe AE-COPD, This might provide new insights in understanding the potential interactions between the fungal microbiome and the pathogenesis of COPD.

In conclusion, it is time that we broaden our outlook, when we attempt to make a search for an aetiological agent causing an acute exacerbation of COPD. Early identification of potential fungal agents in vulnerable population, would help target treatment accordingly, and thereby reduce mortality, morbidity and prevent future exacerbations, which are the goals of COPD treatment as envisaged by the GOLD guidelines.

References

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary. *Eur Respir J* 2017; 49: 1700214.
2. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2000;161(5):1608–1613.
3. Pozo-Rodriguez F, Lopez-Campos JL, Alvarez-Martinez CJ, et al. Clinical audit of COPD patients requiring hospital admission in Spain: AUDIPOC study. *PLoS One*. 2012;7(7):e42156.
4. Delsuc C, Cottreau A, Frealde E, Bienvenu AL, Dessein R, Jarraud S, et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. *Crit Care*. 2015; 19:421. <https://doi.org/10.1186/s13054-015-1140-1> PMID: 26631029; PubMed Central PMCID: PMC4668635.

5. Huerta A, Soler N, Esperatti M, Guerrero M, Menendez R, Gimeno A, et al. Importance of *Aspergillus* spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGICOPD study. *Respir Res.* 2014; 15:17. <https://doi.org/10.1186/1465-9921-15-17> PMID: 24517318; PubMed Central PMCID: PMC396133.

6. Yoshimura K, Suzuki Y, Inoue Y, et al. Utility of serum *Aspergillus* – galactomannan antigen to evaluate the risk of severe acute exacerbation of chronic pulmonary disease. *PLoS One.* 2018 Jun 5;13(6):e0198479. doi: 10.1371/journal.pone.0198479. eCollection 2018.

Review Article

Airborne Infection Control in Health Facilities

Rakesh P.S.

Medical Consultant, World Health Organisation
RNTCP Technical Assistance Project, Kerala.

Airborne transmission of infectious diseases like tuberculosis (TB), H1N1, severe acute respiratory syndrome (SARS), coronavirus, etc is a major public health concern. India continues to have the highest number of tuberculosis (TB) cases in the world.¹ The airborne transmission becomes even more prevalent in health-care settings because of overburdened and overcrowded hospitals and the presence of patients with immunosuppression.² Nosocomial outbreaks of air borne infections in many countries have focused attention on the need to control the transmission of the disease in hospital.³

Emerging infectious diseases like Nipah virus disease has caused mortality among health care workers and general population with substantial nosocomial transmission.⁴ The death of a nurse who treated the patients with Nipah virus disease at recent outbreak in Kerala caught widespread attention.⁴ A systematic review of 51 studies conducted in low- to middle-income countries found that TB incidence among health care workers was high, ranging from 69 to 5780 per 100,000.⁵ Evidences show that TB is a significant occupational problem among health care professionals. Nosocomial outbreaks of airborne infections like influenza H1N1, drug-susceptible, multidrug-resistant TB (MDR TB), and extensively drug-resistant TB (XDR TB) have been reported and have been linked to the absence or limited application of airborne infection-control strategies in health care facilities.⁶⁻⁹

Several factors may facilitate nosocomial transmission in Indian hospitals, although their relative

importance in facilitating transmission is unknown. Risk of transmission is highest when there is a high number of cases with poor infection control. Undiagnosed cases especially at medical ICUs and emergency rooms pose great threat for nosocomial transmission.¹⁰ Prevailing infection control practices in India revolve around biomedical waste management and disposal of sharps; while airborne infection control (AIC) measures has not received adequate attention from the health care facilities and practices. National Guidelines on Airborne Infection Control in Health Care and other settings in India were published as the first, formal national guidelines on reducing the risk of airborne infections in health care facilities and special high-risk settings in India.¹¹

The guideline involves recommendations categorized into three main components;

- I. Administrative controls.
- II. Environmental controls.
- III. Use of Personnel protective equipment.

I. Administrative controls:

Administrative controls are to classify persons with respiratory symptoms, separate them into appropriate environment, fast-track them through the health care facility to reduce exposure time to others, and diagnose/treat them with minimal delay.

A. Outpatient Setting

a. Screening : Screening for respiratory symptoms need

to occur as early as possible upon patient's entry at the health care institution. A separate screening counter may be placed, patients can be encouraged to first visit this counter if they have suggestive symptoms, by appropriate advertisements, posters or announcements in the registration area. Even if screening at registration is not possible, screening can occur when patients register at specific clinics or when in waiting areas.

b. Education on cough etiquette and respiratory hygiene:

This is a physical method that can prove useful for reducing airborne transmission. There should be provision for patient education on cough hygiene and sputum disposal. This education can easily be imparted to patients through posters and other means in the waiting area. Cough etiquette should be reinforced by all staff members. Masks can be provided to all respiratory symptomatics. Simple surgical masks may not help health care worker from getting air borne diseases but are effective when used by the patients to reduce the production of respiratory droplets of all sizes.

c. Patient segregation: Segregation of patients with respiratory symptoms can be achieved by having a separate waiting area for chest symptomatics, within the overall outpatient area. This is particularly important in larger institutions with heavy OPD loads. The outpatient area, more so this segregated area, should be well ventilated to reduce overall risk of airborne transmission.

d. Fast tracking of patients with respiratory symptoms:

Those identified as patients with respiratory symptoms can be further fast-tracked in both their clinical and laboratory evaluation. Patients may be allowed to jump the routine queue and be seen earlier than other patients. The other important area where these patients can be given priority is while performing chest radiography.

B. Inpatient areas

a. Minimize hospitalization of TB patients: This is one of the most effective means to reduce the risk of transmission of airborne pathogens such as M. tuberculosis in hospital settings is to manage such patients in the outpatient setting whenever possible.

b. Establish separate rooms, wards, or areas within wards

for patients with infectious respiratory diseases: Patients with infectious respiratory diseases should be physically separated from other patients so that others are not exposed to the infectious droplet nuclei that they generate. Policies on patient separation inevitably generate concern about stigma, but with appropriate measures - such as training and public posting of separation rules - stigma can be minimized. Administrative procedures should ensure that separation happens promptly and automatically, similar to the automatic separation of men and women during inpatient admission. The best choice for infectious or potentially-infectious patients is to house and manage them in airborne precaution rooms.

c. Educate inpatients on cough hygiene and provide adequate sputum disposal:

Wards housing infectious patients should display sign boards in the ward demonstrating cough hygiene. All patients admitted in the ward/area should be issued surgical masks and counseled on their proper use and adequate measures for safe collection and disposal of sputum.

d. Establish safe radiology procedures: Patients with infectious respiratory disease like TB can have the scheduling of the procedure during non-busy times

II. Environmental Controls:

Ventilation should be prioritized to reduce the number of infectious particles in the air. Effective ventilation may be achieved by natural ventilation where ever possible. When clean or fresh air enters a room, it dilutes the concentration of airborne particles, such as droplet nuclei, in room air.

Unrestricted openings (i.e. those that cannot be closed) on opposite sides of a room provide the most effective natural ventilation. Openings should constitute at least 20% of the floor areas (10% on either side for effective cross ventilations). In existing health-care facilities that have natural ventilation, when possible, effective ventilation should be achieved by proper operation and maintenance of openings, and by regular checks to see that openings remain free of obstruction at all times.

Mechanical ventilation with or without climate control may appropriate where natural ventilation

cannot be implemented effectively, or where such systems are inadequate given local conditions (e.g. building structure, climate, regulations, culture, cost and outdoor air quality). If mechanical ventilation is used, the system should be well designed, maintained and operated, to achieve adequate airflow rates and air exchange. Careful attention must be given to ensuring adequate ventilation when installing air conditioners. Minimum number of air changes per hour need to be ensured while using air conditioners. In OPD and registration areas there should be minimum of 6 air changes per hour while in high risk setting it should be 12.

In high-risk settings where optimal ventilation cannot be achieved through natural or mechanically-aided means, properly designed, placed and maintained shielded ultraviolet germicidal irradiation devices should be considered as a complementary control.




Fig. 1 : Schematic showing seating arrangement for patient and health care worker (red cross)

In (A), natural ventilation would allow potentially infected air to cross health care worker. In (B), with this seating arrangement the chance of such exposure is lessened somewhat. (Picture adapted from NAIC guidelines, 2010).

Other means include UV lamps, air filters, etc. However these have to be placed in the most useful way and need periodic maintenance, in the absence of which they offer no protection. Negatively ventilated rooms also can be constructed, however these require a huge investment on construction as well as regular maintenance.

III. Personal protective equipment:

Simple surgical masks may not help health care worker from getting air borne diseases but are effective when used by the patients to reduce the production of respiratory droplets of all sizes. Personal protective equipment (e.g. particulate respirators certified as N95 or FFP2) should be available as required in high-risk situation, especially during high-risk aerosol-generating procedures such as bronchoscopy or sputum induction. Particular respirators are useful only when worn properly and the health care workers have to be trained on proper use of these.

Conclusion

Numerous studies have shown that implementation of recommended air borne infection-control strategies has been associated with reduced outbreaks of air borne infections and preventing its nosocomial transmissions in health care facilities. It is more important to promote implementation of National Air borne Infection Control guidelines in the hospitals. It has been revealed that most of the countries where a significant reduction of air borne diseases including TB has been observed, air borne infection control practices have played a crucial role.

References

1. World Health Organization. Global Tuberculosis Report. 2018. WHO. Geneva.
2. Blachere FM, Lindsley WG, Pearce TA, Anderson SE, Fisher M, Khakoo R, et al. Measurement of airborne influenza virus in a hospital emergency department. *Clin Infect Dis.* 2009;48:438–40
3. Eames I, Tang JW, Li Y, Wilson P. Airborne transmission of disease in hospitals. *J R Soc Interface.* 2009;6: 6(6):S697-702.
4. Govindakarnavar Arunkumar, Radhakrishnan Chandni, Devendra T Mourya, Sujeet K Singh, Rajeev Sadanandan, Preeti Sudan, Balram Bhargava, Nipah Investigators People and Health Study Group; Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018, *The Journal of Infectious Diseases*, , jiy612, <https://doi.org/10.1093/infdis/jiy612>

5. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. *PLoS Med.* 2006;3(12):e494.
6. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. *N Engl J Med.* 1995;332(2):92–98. [PubMed]
7. Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis*. A risk to patients and health care workers. *Ann Intern Med.* 1992;117(3):191–196.
8. Mathew A, David T, Kuruvilla PJ, Jesudasan M, Thomas K. Risk factors for tuberculosis among health care workers in southern India; San Francisco. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA); 2005.
9. Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. *Airborne Infect Control TB HIV Infect Clin Infect Dis.* 2010;50(S3):S231–S237
10. Escombe AR. Huaroto L, Ticona E, Burgos M, Sanchez I, Carrasco L et al. Tuberculosis transmission risk and infection control in a hospital emergency department in Lima, Peru. *14 (9): 2010: 1120-1126(7)*
11. Ministry of Health and Family Welfare. New Delhi: Ministry of Health and Family Welfare; 2010. Guidelines on airborne infection control in healthcare and other settings. Available from: http://www.tbcindia.nic.in/pdfs/Guidelines_on_Airborne_Infection_Control_April2010Provisional.pdf [cited 2January 2019]

Original Article

Pathogenic Fungi in the Environment Causing Acute Exacerbation of COPD and its Link to Coffee Plantations in Wayanad District of Kerala - A Prospective Study

Ravindran Chetambath*, Lakshmipriya Sadananan **, Champa Hemachandra ***

*Professor & HOD, ** Senior Resident, Dept. of Pulmonary Medicine, *** Associate Professor
Dept. of Microbiology, DM Wayanad Institute of Medical Sciences, Wayanad, Kerala, India

Corresponding Author - Ravindran Chetambath

Navaneeth, Sarovaram Road, Calicut, Kerala- 673020

Email; crcalicut@gmail.com

Abstract

Background : Majority of exacerbations of COPD (AECOPD) are due to infections. Usual agents causing AECOPD are gram negative bacteria, but rarely viruses and fungi are also implicated. Wayanad is a hill district with predominant coffee and tea plantations. Coffee berries ripe in the months of October to January. Branches of coffee plants and berries carry white flakes which are fungi rich. These flakes are dispersed in the environment and we are looking at the possibility of this increased concentration of fungal spores in the environment during this period as a possible cause of fungal infections in AECOPD.

Objectives : 1) To study the prevalence of fungal infection among hospitalized patients with AECOPD during coffee crop season 2) To identify a causal relationship with increased fungal spores in the environment during coffee crop season.

Methods : Patients admitted with AECOPD for a period of 4 months from 1st October 2017 to 31st January 2018 are prospectively included from ICU and general ward of Pulmonary Medicine Department of a tertiary care hospital. Clinical, radiological and microbiological data are collected at admission and during the hospital stay. Clinical course and outcome are recorded. A detailed search was made by collecting samples for fungal culture from the surroundings including the plantations to demonstrate growth of fungi.

Conclusion : There is high prevalence of fungal isolation in a cohort of COPD patients with severe AECOPD requiring hospitalization. Diabetes mellitus is found to be an independent risk factor for fungal isolation. Fungal growth is correlated with longer duration of hospital stay and increase in death rate. Many pathogenic fungi were isolated including *Aspergillus fumigatus* from samples collected from coffee plants and berries during this period. *Aspergillus fumigatus* is found to be the most common fungi isolated from patients with AECOPD.

Keywords : Coffee Plants, AECOPD, Fungal Spores, *Aspergillus fumigatus*.

Introduction

Exacerbations of chronic obstructive pulmonary disease (COPD) are frequent events in the natural history of the disease, considerably increasing the morbidity and mortality¹. Acute exacerbations of COPD (AECOPD) are characterized clinically by worsening of dyspnoea, increased sputum production and/or changes in sputum purulence². There is evidence suggesting that infectious agents, induces AECOPD by increasing bronchial and systemic inflammation³. Microbial infections account for the etiology of 75% of AECOPD⁴. However, the role of microorganisms other than bacteria has not been well established. Viral infections causing AECOPD are frequently reported. *Aspergillus* spp. may be responsible for important clinical events from saprophytic colonization of the airways to rapidly invasive and life-threatening disseminated diseases. This is attributed to the reduced immune status of the host due to the presence of underlying lung disease⁵, comorbid illnesses such as diabetes and use of broadspectrum antibiotics and corticosteroids⁶. Some retrospective studies have analyzed the incidence of *Aspergillus fumigatus* isolation from lower respiratory tract samples in AECOPD patients and shown that COPD patients are an important group which are affected by either colonization or proven aspergillosis⁷. In one of the largest studies investigating the prevalence, *Aspergillus* was isolated from respiratory samples of 36 patients out of a total of 1756 patients⁸. However, it remains unclear whether COPD patients are colonized by *Aspergillus* spp. or they have invasive pulmonary disease. It is difficult to define the influence of this organism as a causal agent of exacerbations unless invasive infection is proved by histopathological examination.

The state of Kerala has a humid tropical climate with an average annual rainfall of 300 cm. The typical climatic and other physiographic factors offer hostile environment for a large number of microorganisms like fungi⁹. Wayanad district in Kerala is a hilly farm land having coffee and tea plantations. Coffee plants and berries show fungal growth which are dispersed during crop season. This may increase the quantities of fungal spores in the environment. Thus, this study was initiated to analyze the prevalence of fungal infection in AECOPD during coffee crop season and to identify the environmental source of fungus. Efforts are made to

link the environmental source of fungus to coffee plantation in the district.

Objectives

- 1) To study the prevalence of fungal infection among hospitalized patients with AECOPD during coffee crop season.
- 2) To identify a causal relationship with increased fungal spores in the environment during coffee crop season.

Methods

Study design

A : Data are prospectively collected after informed consent from patients hospitalized due to a COPD exacerbation in a tertiary teaching hospital in Wayanad district between 1st October 2017 and 31st January 2018. This period is selected because this is the season in which coffee plants flower and berries ripe. Approval from institutional ethics committee (IEC) is obtained for this study.

B : Samples are collected in petri dishes from branches and berries of coffee plants from 5 different coffee plantations within the districts. The white flakes over dry berries and offshoots carrying the berries are selectively collected and sent to microbiology laboratory for processing (Fig-1).



Fig 1 : Coffee plant with dry berries. Black arrow shows white flakes containing fungi

Study protocol

Only known COPD patients as per previous hospital records and on treatment for COPD for more than one year are included. All patients admitted in the pulmonary medicine ward or ICU are evaluated clinically and investigated with complete blood count, X-Ray Chest PA, spirometry, sputum gram stain and culture, fungal smear and culture, bronchoscopy and bronchial washings for bacterial and fungal culture and CT Thorax in selected cases. COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy. Diagnosis of COPD exacerbation, decision to hospitalize, time of discharge and choice of pharmacological therapy were taken by the physician in charge. All the patients are put on standard treatment for exacerbations as per GOLD guideline. Patients in whom fungal growth is detected are subsequently put on itraconazole/ voriconazole in standard adult dose. Patients with active tuberculosis, asthma, renal failure or any other clinical respiratory diseases are excluded. Clinical course and outcome of all patients are recorded. Outcome reported are discharge or death.

Data collection

Demographic variables, presence of any comorbid conditions (Hypertension or diabetes), smoking status, use of steroids (Systemic or inhaled) were recorded on admission to hospital. Symptoms/signs of the AECOPD together with physiological and laboratory data are collected at onset. Other variables such as length of stay (LOS), frequency of patients in whom admission to the intensive care unit (ICU) is needed, requirement of non-invasive mechanical ventilation (NIMV) and death are recorded. The number of AECOPD events in the year preceding hospitalization is assessed based on treatment records. Only exacerbations requiring emergency room visits or admissions are included.


Microbiological analysis

When patients admitted into hospital, their sputum samples were collected in a sterile container with adequate precautions and transported immediately to the microbiological laboratory. Microbiological examinations included direct microscopy (Gram stain &

KOH mount), bacterial and fungal culture. All the patients were subjected to fiberoptic bronchoscopy after obtaining written consent. Bronchial washings after saline instillation was recovered and sent for microscopy and culture for bacteria and fungi immediately. All samples were cultured on conventional media, including blood agar, chocolate agar and McConkey agar which were incubated at 37°C for 48 hrs. The samples were also inoculated on Sabouraud's dextrose agar and incubated at 37°C and 25°C for 7 days and observed for growth of fungi each day and the number of visible colonies recorded.

Bronchial biopsy was taken from patients in whom bronchial inflammation is seen. This is subjected to bacterial and fungal culture and histopathological examination. Bacterial infection was confirmed when there is a colony count $\geq 10^5$ cfu/mL. All the fungi grown were subjected to slide culture. The fungal spp. grown was identified based on macroscopic features and microscopic appearance.

33 samples collected in petri dishes from coffee plants and coffee beans from 5 different plantations in the district are transported to microbiology laboratory and one part is processed with KOH mount for fungal elements. Remaining part was inoculated in Sabouraud's Dextrose agar for fungal culture. KOH smear showing fungal mycelia are recorded. Culture is examined after 7 days for colonies and species identified by macroscopic and microscopic methods (Fig-2, Fig-3).






Fig 2 : Growth of fungi in samples collected from Coffee plants. A, B: *Aspergillus fumigatus*, and C, D: *Aspergillus niger*





Fig 3 : Growth of fungi in samples collected from Coffee plants. A: *Rhizopus* spp., B, C: *Fusarium* spp., D: *Mucor* spp.

Statistical analysis

Data are analyzed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Categorical variables are presented as absolute numbers and relative frequencies, while continuous variables are presented as the mean, standard deviation (SD) in parametric data, or median with the interquartile (IQR) range in non-parametric data. Categorical variables are compared using the χ^2 test.

Results

Number of subjects treated for COPD exacerbation during the study period was 106. Mean age of the patients were 75.5 years. Study subjects include 97 (93.3%) males and 9 (6.7%) females (Table-1). All the males were reformed smokers and 2 females were smokers. All the female patients had exposure to biomass fuels. Among the study subjects, 17 (16.3%) patients had fungi cultured from sputum or bronchial washings. All the 17 patients

had *Aspergillus fumigatus* and 2 of them were co-infected with *Mucor* spp. No other fungal species were detected from these subjects. Among those above 65 years 17% had fungal cause for exacerbation and those below 65 years 15% had fungal cause for exacerbations (Fig-4, Table-1). All the patients had treatment with inhaled corticosteroid and antibiotics during previous exacerbation and during the present admission. Hence use of these two agents cannot be attributed to the increased rate of fungal infections. There were 17 diabetic patients in this cohort out of which 35% has fungal infection whereas among the non-diabetic 12.4% only had fungal infection. This is statistically significant (Fig-5, Table-1). When we looked at duration of hospital stay it is found that 95% of patients who had a hospital stay of more than 10 days had fungal infection (Fig-6, Table-2). This is found to be statistically significant. Case fatality among AECOPD patients in this study was 7(6.6%) and death among those having fungal infection was 3 (17.6%) (Fig-7, Table-2).

	AECOPD with fungal Infection, n=17	AECOPD without fungal Infection, n=89	PValue
Demographics			
Age in years	76 ± 7	75 ± 8	0.741
Gender (male/female)	14/3	83/6	0.092
BMI(kg/m ²)	23.4 ± 3.1	24.1 ± 3.6	0.266
Smoking history, n (%)	15 (88.2%)	80 (89.9%)	1.000
COPD characteristics(post bronchodilators)			
FEV ₁ %	42.0 ± 14.0	44.1 ± 12.8	0.261
GOLD grade			
Grade I	2 (11.7%)	15 (16.8%)	
Grade II	4 (23.4%)	23 (25.8%)	
Grade III	10 (58.8%)	44 (49.4%)	
Grade IV	1 (5.9%)	7 (7.9%)	
GOLD grade ≥ 3, n (%)	11 (64.7)	51 (57.3)	0.744
Underlying conditions, n (%)			
Hypertension	7 (41.2%)	24 (27.0%)	0.082
Diabetes Mellitus	6 (35.3%)	11 (12.4%)	0.032
Drug Usage on admission			
Corticosteroids use, n (%)	17 (100%)	89 (100%)	0.000
Broad spectrum antibiotics	17(100%)	89 (100%)	0.000
Long term oxygen therapy	6 (35.2%)	18 (20.2%)	0.353
Times of AECOPD in previous year	1.7 ± 1.3	1.3 ± 1.1	0.186

Table 1 : Basic information of study subjects




Fig 4 : Characteristics of fungal infection in AECOPD




Fig 5 : Fungal infection in relation to T2 DM

	AECOPD with fungal Infection, n=17	AECOPD without fungal Infection, n=89	P Value
Admitted in ICU	4 (23.5%)	16 (18.0%)	0.802
Machanical ventilation	2 (11.8%)	9 (10.1%)	0.906
LOS >10 days	6 (35.3)	8 (9.0%)	0.037
Improved	14(82.35%)	85(95.5%)	0.901
Death	3(17.6%)	4 (4.49%)	0.084

Table 2 : Short-term outcomes in AECOPD patients




Fig 6 : Relationship between fungal infection in AECOPD and LOS




Fig 7 : Outcome due to fungal infection in AECOPD

All samples collected from coffee plantations showed fungal elements in KOH mount. On culture growth was observed in 30 samples (90.9%). On macroscopic cultural characteristics and microscopic features the species identified were *Aspergillus fumigatus*, *Aspergillus niger*, *Mucor* spp., *Rhizopus* spp and *Fusarium* spp. (Table-3) (Fig-2&3).

Fungi isolated	Number of isolations, n=30	Percentage
<i>Aspergillus fumigatus</i>	25	83.34
<i>Aspergillus niger</i>	2	6.67
<i>Rhizopus</i> spp.	1	3.33
<i>Mucor</i> spp.	1	3.33
<i>Fusarium</i> spp.	1	3.33
<i>Aspergillus fumigatus</i> + <i>Rhizopus</i> spp.	2	6.67
<i>Aspergillus fumigatus</i> + <i>Mucor</i> spp.	2	6.67
<i>Aspergillus fumigatus</i> + <i>Fusarium</i> spp.	4	13.33

Table 3 : Distribution of the various fungi isolated from the coffee beans.

Discussion

Fungi are microorganisms commonly found as both endo and epiphytic symbionts of plants and their products. During the fruit stage and at further steps of coffee bean processing, different species of fungi are seen. This is more important because of the fact that coffee berries are hand plucked by laborers, thus helping in dispersing fungal spores in the environment. Those working in coffee plantations are at higher risk of exposure. From 5,000 sampled coffee beans, 1,433 (28.66%) produced no microorganisms in culture while from the remaining 3,567 (71.34%) beans at least one microorganism was isolated in Petri dishes. A total of 2,525 (70.78%) beans produced strains of fungal taxa in which toxigenic species are commonly found (e.g. *Penicillium*, *Aspergillus*, *Fusarium*)¹⁰.

Moulds growing on food, damp walls or compost piles produce millions of spores that are frequently inhaled by humans and can cause diseases ranging from simple asthma to life-threatening illnesses such as invasive bronchopulmonary aspergillosis (Fig-8). All sampling series show high proportion of *Aspergillus* and *Penicillium* species, including potentially pathogenic species such as *Aspergillus fumigatus*¹¹.




Fig 8 (A)




Fig 8 (B)

Fig 8 (A) *Aspergillus tracheobronchitis* in a 79 year old male admitted with AECOPD (Red arrow), Fig-8 (B) Histo-pathological slide demonstrating dichotomous branching mycelia of *A. fumigatus*¹²

Aspergillus spp. is a ubiquitous fungus in the environment with high sporulation capacity¹³. After *Aspergillus* sporulates, conidia with a diameter of 2–3 μm are released into the air, this enters the airway, and reach alveoli⁵. Therefore, the lung is the main organ affected by *Aspergillus*. *Aspergillus* spp. causes various diseases in lungs, such as *Aspergillus* colonization, *Aspergillus* infection and allergic bronchopulmonary aspergillosis¹⁴. In COPD patients, impairment of the defense mechanisms of airways facilitates the binding of conidia to epithelial cells, which may cause *Aspergillus* colonization in the airway¹⁵. Positive isolation of *Aspergillus* spp. in LRT samples from COPD patients is common, and a previous study reported that the positive identification rate was nearly 29%⁷. This is the first study in this part of the country to prospectively determine the prevalence of fungal infection, associated risk factors and outcome in a cohort of AECOPD patients requiring hospitalization. We have shown that the prevalence of fungal isolation in this cohort was 16.3% on admission. The independent risk factor associated with fungal infection in this cohort was diabetes mellitus which is clinically and statistically significant with a p value of 0.032. Fungal isolation was associated with clinically and statistically significant outcomes such as increased duration of hospital stay

(p value 0.037) and death (p value 0.084). In a prospective study Auturo et al reported that patients with *Aspergillus* spp. isolation had significantly higher LOS compared to those patients without *Aspergillus* spp. isolation (7.5 ± 5.0 days versus 11.8 ± 9.2 days, $p = 0.02$)¹⁶. Mortality among these patients was marginally higher when fungal isolation was established. Mortality rate in association with fungal infection in COPD patients is believed to be high because of the difficulty in reaching an early diagnosis. However Auturo et al did not find any significant differences in any of the other clinical outcomes when comparing patients with and without *Aspergillus* spp. isolation¹⁶.

In a hilly agricultural district of Wayanad where the predominant cultivation is Coffee and tea we were looking for different causal factors leading to AECOPD. This is mainly because during ripening of coffee beans fungal flakes are released to the atmosphere in large quantities. So we thought of looking for fungal infection during this period, that is October to January. The prevalence of fungal isolation is found to be equal or higher in this study when compared to earlier studies. In a study by Pashley et al.⁷ the isolation of *Aspergillus fumigatus* in sputum culture was significantly higher using a research approach compared to the standard method for mycological investigations. There are few previous studies, reporting different prevalence rates of fungal isolation in respiratory samples from patients with COPD^{8,17}. Recently, a large, retrospective study conducted by Guinea et al¹⁸, analyzed the incidence of *Aspergillus fumigatus* isolation from lower respiratory tract samples in patients admitted for AECOPD in a tertiary hospital. They reported 239 isolations of *Aspergillus* spp. (16.3 per 1000 admissions), and our study shows much higher prevalence (16.3%). It is interesting to note that we could isolate *Mucor* spp. in two samples among this cohort.

Out of the 33 samples collected from different coffee plantations in the district, 30 showed fungal isolation. All the fungi isolated were pathogenic and the most frequent isolation was that of *Aspergillus fumigatus* (83.34%). This is the species mostly isolated from respiratory secretions of patients in this cohort. Two patients also had co-infection with *Mucor* species which is isolated from three of the environmental samples.

Conclusion

There is a high prevalence of fungal isolation in a cohort of COPD patients with severe AECOPD requiring hospitalization. Diabetes mellitus is found to be an independent risk factor for fungal infection. Fungal infection in COPD is correlated with longer duration of hospital stay and increase in death rate. *Aspergillus fumigatus* is the fungi causing AECOPD in this cohort and this species was isolated from majority of samples collected from coffee plantations.

Conflicts of interest

Authors have no conflicts of interests to declare. This study is not funded by any agency.

References

1. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochoa R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005; 60 (11): 925-31. (PubMed, Google Scholar)
2. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med.* 1987; 106 (2): 196-204. (PubMed, Google Scholar).
3. Rosell A, Monso E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. *Arch Intern Med.* 2005; 165 (8): 891-97.
4. Wedzicha JA, Seemungal TA: COPD exacerbations: defining their cause and prevention. *Lancet.* 2007; 370 (9589): 786-96.
5. Bulpa P, Dive A, Sibille Y: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. *EurRespir J.* 2007; 30 (4): 782-800.
6. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, et al. Isolation of *Aspergillus* spp. from the respiratory tract in critically ill patients: risk factors, clinical

- presentation and outcome. *Crit Care*. 2005; 9 (3): R191-R199. (PubMed, PubMed Central, Google Scholar)
7. Pashley CH, Fairs A, Morley JP, Tailor S, Agbetile J, Bafadhel M, et al. Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. *Med Mycol*. 2012; 50 (4): 433-38. (PubMed, PubMed Central, Google Scholar).
 8. Borman AM, Palmer MD, Delhaes L, Carrere J, Favennec L, Ranque S, et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. *Med Mycol*. 2010; 48 (Suppl 1): S88-S97. (PubMed, Google Scholar).
 9. M Thomas, A Varghese, R Rajan, KA Samuel, PKurian. Checklist of microfungi in Kerala, India. *Asian Jr. of Microbiol. Biotech. Env. Sc*. 2011; 13 (4): 651-58.
 10. Miguel Ángel Gamboa-Gaitán. Presence of Aspergillus and other fungal symbionts in coffee beans from Colombia. *Acta biol. Colomb*. 2012; 17 (1): 39-50.
 11. Doris Haas, Susanne Lesch, Walter Buzina, Herbert Galler, Anna Maria Gutschi, et al. Culturable fungi in potting soils and compost. *Medical Mycology* 2016; 54 (8): 825-34
 12. R. Dheeraj, S. Amitha, S. Sanjeev, Mohammed Aslam, Ravindran Chetambath. Invasive Aspergillus Tracheobronchitis Presenting as an Intraluminal Mass - A Rare Case. *The Indian Practitioner* 2018; 71 (6):30-33.
 13. Latgé JP. The pathobiology of aspergillus fumigatus. *Trends Microbiol*. 2001;9(8):382-9.
 14. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. *Chest*. 2002;121(6):1988-99.
 15. Latgé JP. Aspergillus fumigatus and aspergillosis. *Clin Microbiol Rev*. 1999;12(2):310-50.
 16. Arturo Huerta, Nestor Soler, Mariano Esperatti, Mónica Guerrero, Rosario Menendez, Alexandra Gimeno, et al. Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. *Respir Res*. 2014; 15(1): 17-25.
 17. Agbetile J, Fairs A, Desai D, Hargadon B, Bourne M, Mutalithas K, et al; Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1. *Clin Exp Allergy*. 2012; 42 (5): 782-91. (PubMed, PubMed Central, Google Scholar).
 18. Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. *Clin Microbiol Infect*. 2010; 16 (7): 870-77. (PubMed, Google Scholar).

Original Article

Utility of EBUS - TBNA in Mediastinal Lymphadenopathy in a Tertiary Care Centre

Bala P.*, Ameer K. A., Arjun P.**, Vinod Kumar Kesavan****

*DNB resident, **Senior consultant, Department of Respiratory Medicine
Kerala Institute of Medical Sciences, Thiruvananthapuram.

Abstract

Context

Diagnosis of mediastinal lymphadenopathy requires tissue sampling. This can be done by invasive or minimally invasive procedures. The current trend is moving towards less invasive, faster, cheaper and safer procedures.

Aim and objectives

The aim of this study is to assess the usefulness and yield of endobronchial ultrasound guided trans-bronchial needle aspiration (EBUS-TBNA) in patients with mediastinal lymphadenopathy.

Study setting and design

The study is a hospital record-based study conducted in Kerala Institute of Medical Sciences, Trivandrum. The study population included patients with mediastinal lymphadenopathy who were subjected to EBUS-TBNA during the period from March 2015 to September 2018. The results of the study population were analyzed.

Results

In this study, the median age of the study population was 53.27 years with a standard deviation (sd) of 14.02. 78 were males and 45 were females. There was adequate sampling in 109 cases giving a positive yield of 88.61%. Overall, EBUS-TBNA was diagnostic in 87 cases (70.73%). Most common diagnosis was malignancy (38.21%), followed by granulomas (32.52%). Among 36 patients with inconclusive results, 21 patients had atypical cells, reactive lymphoid tissue and fibrinous material whereas in 14 patients the samples were inadequate. 8 patients had necrotizing granulomas typical of tuberculosis out of which only 1 patient came positive for AFB culture and AFB smear and 2 patients had positive CBNAAT. The yield of EBUS in suspected malignancies was 65.08% and suspected sarcoidosis was 86.96%.

Conclusion

EBUS-TBNA is a bronchoscopic procedure with very good yield. In our study, malignancy was the most common diagnosis followed by granulomatous conditions.

Introduction

Mediastinal lymphadenopathy can be due to variety of causes ranging from benign to malignant diseases. The evaluation of mediastinal lymphadenopathy is very important for staging in suspected/proven lung cancer. A definitive diagnosis can only be acquired by tissue sampling which can be done by invasive or minimally invasive methods. Mediastinal nodes are classified basically into anterior, middle and posterior based on the compartment it is located. The current classification of mediastinal nodes is based on IASLC (International association of study of lung cancer) which has divided it into ten groups. Invasive procedures like mediastinoscopy and VATS biopsy are performed by cardiothoracic surgeons. Recent advances in bronchoscopy has allowed pulmonologist to do ultrasound localization of the mediastinal nodes and sampling it with better yield, greater speed and lower rate of complications.

The concept of TBNA (Trans-bronchial needle aspiration) first came in 1949. Dr. Eduardo Schieppati first reported the employment of TBNA without obtaining full attention of clinicians¹. Then in 1978, Wang et al introduced this technique to North America and promoted it to the whole world by describing TBNA in diagnosing small cell lung cancer². EBUS(Endo-bronchial Ultrasound) is a bronchoscopic technique that uses ultrasound to visualize structures within and around airway and lung parenchyma. Historically, transbronchial needle aspiration done in a blind manner was always under-utilized. Recent advancement with ultrasonography lead to resurgence of TBNA. Endobrochial ultrasound in combination with TBNA was first developed in 2002. By 2007, EBUS-TBNA had been accepted by clinicians as a safe and efficient technique for mediastinal and hilar lymphadenopathy^{3,4}. In India, the use of EBUS-TBNA is on the rise for the past few years although, many clinicians across the country are not familiar with the utility and procedure details of EBUS.

Endobrochial ultrasound in combination with TBNA is used to diagnose a new lung cancer and also for staging and re staging a known lung cancer. EBUS is also used for evaluating mediastinal lymphadenopathy of unknown etiology. Using the

EBUS-TBNA we can sample the paratracheal lymph node stations (2R & L, 4R & L), subcarinal node(Level 7), hilar (Level 10 R & L), subaortic (5) and interlobar (11R & L). Mediastinoscopy does not have access to the latter two stations⁵. The main advantages of EBUS are cost effectiveness, good yield and acceptable safety profile. The guidelines from American college of chest physicians (ACCP)⁶, National Institute of Health and Care Excellence (NICE)⁷, and European Respiratory Society (ERS)⁸ all recommend the use of EBUS in patients with suspected/proven lung cancer for mediastinal staging. The diagnostic yield of EBUS-TBNA has been found non-Inferior to mediastinoscopy⁹. The diagnostic yield of EBUS-TBNA have been proven previously in different studies conducted in India eg.,Gahlot et al¹⁰ -92%, Dhamija et al¹¹- 88% and Srinivasan et al¹²- 62%.

This study was done to evaluate the usefulness and yield of EBUS-TBNA in patients with mediastinal lymphadenopathy in our tertiary care institute.

Methodology

Study design

A hospital record-based study was conducted in the department of Respiratory medicine, Kerala Institute of Medical Sciences Trivandrum. The study population included patients coming mainly from southern parts of Kerala and Tamil Nadu with mediastinal lymphadenopathy. After discussing with the subject experts, a study protocol was made and the needed variables were determined. The study protocol included general baseline characteristics like age and sex, symptoms, initial clinical diagnosis, final pathological and microbiological results and CT chest. Data were collected from Electronic medical records of patients who were subjected to EBUS-TBNA for evaluation of mediastinal lymphadenopathy during the period of March 2015-September 2018.

Procedure

The procedure is done as an outpatient one, either under conscious sedation with Midazolam (2-5 mg IV) and Fentanyl (1-2 mcg/kg IV) or under general anesthesia with LMA(laryngeal mask airway) in few selected patients. The procedure was done with an

EBUS Bronchoscope(BF-UC180F) under ultrasound and color Doppler guidance with either 21 or 22 Gauge needles. The lymph nodes of stations- 2, 4, 5,7, 10 and 11 on either sides are localized using convex ultrasound probe and sampled. Specimens obtained by needle aspiration were made into smears on slides and kept in alcohol based solution for cytopathological examination. Dry smears are also made for AFB staining. Needle core specimen obtained by using suctioning were kept in formalin solution and were sent for histopathological examination. Few core specimens were kept in saline and sent for mycobacterial investigations. Rapid on-site evaluation (ROSE) was not done in our study due to unavailability of on-site pathologist.

The diagnostic yield was studied by pathological and microbiological results of the samples taken by EBUS-TBNA.

Being a record based study, permission of the gatekeeper of information was obtained and patient identifiers were not extracted.

Data storage and analysis

Data collected were entered in Excel spreadsheet and descriptive analytics done with Epi info 7.

Results

The mean age of the study population was 53.27 years with an sd of 14.02. 55 patients were in the age group of 40-60 years and 43 patients were above 60 years. 78 patients were males and 45 were females. The most common presenting symptom was cough which was seen in 77 patients(62.60%) followed by dyspnea and loss of weight. 16 patients were asymptomatic- out of which 9 patients were having known malignancies where EBUS-TBNA was done to rule out mediastinal nodal metastasis and 4 patients had an incidental mediastinal lymphadenopathy during visa medical check-up where EBUS-TBNA was done to rule out tuberculosis. 3 patients presented with symptoms of extra pulmonary tuberculosis and mediastinal lymph nodes were sampled using EBUS TBNA.

Characteristics		Number	Frequency
1. Age	a. Less than 40	25	20.33%
	b. 40 to 60 yrs	55	44.72%
	c. 60 yrs and above	43	34.96%
2. Sex	Male	78	63.41%
	Female	45	36.59%
3. Symptoms	Cough	77	62.60%
	Hoarseness	15	12.20%
	Loss of weight	13	10.57%
	Fever	8	6.50%
	Dyspnoea	17	13.82%
	Hemoptysis	8	6.50%
	Asymptomatic	16	13.01%

Table 1 : Baseline Characteristics of the study population (n=123)

Cytopathological and histopathological examinations revealed definitive diagnosis in 87 (70.73%) patients out of 123, with malignancy seen in 47 patients (38.21%), granuloma seen in 40 patients (32.52%) and inconclusive in 36 patients (29.27%). Among the inconclusive results, atypical cells and reactive lymphoid tissues were seen in 13 patients, fibrinous material was obtained in 9 patients and in 14 patients (11.38%) the specimen was reported as inadequate in which no definite pathology was identified and only scanty material was aspirated.

Among malignancy, most common carcinoma was adenocarcinoma seen in 24 cases, squamous cell carcinoma in 11 patients, neuroendocrine tumors in 10 patients and 1 patient came as B cell lymphoma. Finally, one patient who is a known case of lung carcinoma who was subjected to EBUS TBNA for staging came positive for adenocarcinoma metastasis.

H P E	Frequency	Percent	95% confidence intervals	
			Lower	Higher
Adenocarcinoma	24	19.51%	12.92%	27.63%
Squamous cell ca	11	8.94%	4.55%	15.44%
Neuroendocrine tumor	10	8.13%	3.97%	14.44%
Granuloma without features of TB	32	26.01%	18.52%	34.70%
Granuloma suggestive of TB	8	6.50%	2.85%	12.41%
Inconclusive (atypical cells, fibrinous material & inadequate sample)	36	29.27%	21.41%	38.15%
Other malignancy	2	1.63%	0.20%	5.75%

Table 2 : Histopathological examination results (n=123)

Microbiological evaluation was done with AFB smear, CBNAAT and AFB culture. AFB smear was positive in 1 patient (0.81%), AFB culture was positive for mycobacterium tuberculosis in 3 patients (2.44%) and CBNAAT was positive in 2 patients (1.63%).

Comparative analysis was done among different variables which revealed several results. Among 57 suspected TB patients a definitive diagnosis of TB was made with histopathological features (8 patients), AFB culture (2 patients), CBNAAT (2 patients) and AFB smear (1 patient).

AFB Culture	Histopathology		
	Non Necrotizing granuloma	Necrotizing granuloma	Inconclusive
Positive	1	1	1
Negative	31	7	35
AFB smear			
Positive	0	1	0
Negative	32	7	36
CBNAAT			
Positive	0	2	0
Negative	32	6	36

Table 3 : Yield of different tests for Mycobacterium tuberculosis with EBUS

Among 63 suspected malignancy patients, a confirmed malignancy was made in 41 patients and 1 patient turned out to have positive AFB culture and 2

patients had positive CBNAAT. Among 23 suspected sarcoidosis, non-necrotizing granulomatous histo pathology was found in 20 patients (86.96%).

		Number	Percentage
Suspected malignancy (63)	AFB Culture positive	1	1.59%
	CBNAAT positive	2	3.17%
	Histopathology suggestive of Ca	41	65.08%
Suspected sarcoidosis (23)	AFB Culture positive	1	4.35%
	CBNAAT positive		
	Histopathology suggestive of sarcoidosis	20	86.96%

Table 4: Yield for suspected malignancy and sarcoidosis

Post procedure, only 28 patients (22.76%) had minimal hemoptysis for 24 hours and 52 patients (42.27%) had throat pain. No major complications were reported after procedure.

Discussion

In our record based study based on the data from the last 3 years, most of the study population (n=98) is distributed around the ages of 40-60 and above 60. This is in contradiction to the previous studies done in India- Gahlot et al¹⁰. (2011) – mean age- 47 years, Madan K et al¹³. (2014)- mean age- 42.1 years.

There was adequate sampling in 109 cases giving a positive yield of 88.61%. Overall, EBUS-TBNA was diagnostic in 87 cases (70.73%). EBUS was diagnostic in 86.96% of sarcoidosis and 65.08% of malignancy. This is comparable to other studies done in India and western countries. Gahlot T et al¹⁰ reported a diagnostic yield of 92% whereas Madhan K et al¹³ reported a diagnostic yield of 96.1%, Srinivasan et al showed yield of 62.9% and Dhamija et al showed 88%.

International studies like Herth et al¹⁴ reported a diagnostic yield of 93.5%, Yasufuku et al³ reported a diagnostic yield of 100% and YılmazDemirci N et al¹⁵ showed a diagnostic yield of 96.5%. Yield of EBUS-TBNA in sarcoidosis was evaluated in several studies in India and abroad. Madhan K et al¹⁶ did a study comparing conventional TBNA versus EBUS-TBNA for yield in sarcoidosis and they found that yield with EBUS-TBNA without ROSE was 84% for sarcoidosis whereas in our study, it came as 86.96%.

Most common diagnosis in our study was malignancy with 38.21% followed by granuloma- 32.52%. This is in contrast to other Indian studies where most common diagnosis was granulomas- Tuberculosis and sarcoidosis. Srinivasan et al¹² done in northern part of India reported granulomatous conditions like sarcoidosis and tuberculosis as common results (82.1%) and malignancy only in 17.9% cases. Gahlot T et al¹⁰ done in New Delhi also reported granulomatous diseases (77%) as most common finding with TB as main etiology and malignancy seen in only 17% cases. But western studies like Herth et al¹⁴ reported malignancy as the most common final diagnosis (98.20%). Gurioli C et al¹⁷- an Italian case series reported lung cancer as most common final diagnosis (52 out of 94 patients) and granulomatous conditions were seen in 21 patients. The possible reasons could be that the presenting age group in our study is more of 40 years and above and Kerala being a state with low prevalence of tuberculosis comparing other states of the country.

Among malignancies, most common one in our study was adenocarcinoma(n=24) which is consistent with other studies like Herth et al¹⁴ reporting adenocarcinoma in 156 out of 502 patients. Second common malignancy was squamous cell carcinoma followed by neuroendocrine tumors.

Regarding mycobacterium tuberculosis diagnosis with EBUS-TBNA in our study, out of 57 suspected TB patients, 8 patients had necrotizing granulomas characteristic of tuberculosis- of which only one had positive AFB culture, two had CBNAAT positivity and one had smear positivity.

Among 63 suspected lung carcinoma patients, 41 patients proved to be malignant whereas, there were CBNAAT positivity in two patients and AFB culture in

one patient. Thus signifying the importance of tissue sampling of mediastinal lymph nodes and proving the diagnosis.

Among 23 suspected sarcoidosis patients, 20 (86.96%) patient had non necrotizing granuloma suggestive of sarcoidosis and one patient turned to be positive for AFB culture.

Conclusion

Our study showed that EBUS-TBNA is a bronchoscopic procedure with high diagnostic yield (88.61%) for evaluation of cases with undiagnosed mediastinal adenopathy. In our study, malignancy was the most common histopathological finding followed by granulomatous diseases with necrotizing granuloma seen only in 8 patients. 3 out of 63 clinically suspected malignancy cases found to be positive for mycobacterium tuberculosis. There were no major complications associated with the procedure and reported complications were throat pain and mild hemoptysis in a small group of patients.

Acknowledgments

The author would like to thank Dr. Sanjeev Nair, Associate Professor, Department of Pulmonary Medicine, Govt. Medical College, Thiruvananthapuram and Dr. Hisham Moosan, Regional Technical Resource Centre for HTA, Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum for their assistance during analysis & preparation of manuscript.

References

1. Schieppati E. (Mediastinal puncture thru the tracheal carina). *Rev Assoc Med Argent.* 1949 Oct 15-30; 63 (663-664): 497-9. Spanish.
2. Wang KP Terry P, Marsh B. Bronchoscopic needle aspiration biopsy of paratracheal tumors. *Am Rev Respir Dis.* 1978 Jul; 118(1): 17-21.
3. Yasufuku L, Chiyo M, Sekine Y, Chhajed PN, Shibuya K, Ilizasa T, Fujisawa T. Real-time endobronchial ultra sound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. *Chest.* 2004 Jul; 126(1): 122-8.
4. Yang H, Zhao H, Garfield DH, Teng J, Han B, Sun J. Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of non-lymph node thoracic lesions. *Ann Thoracic Me.* 2013 Jan; 8(1): 14-21.
5. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. *The Journal of thoracic and cardiovascular surgery.* 1. 2011;142:1393-1400
6. Ost DE, Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *CHEST J.* 2013;143:e121S-e141S.
7. National Institute for Health and Clinical Excellence (NICE). *The Diagnosis and Treatment of Lung Cancer. Clinical Guideline 121.* London: NICE; 2011.
8. Vilman P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Endoscopy.* 2015;00:545-559.
9. Sampsonas F, Kakoullis L, Lykouras D, Karkoulias K, Spiropoulos K. EBUS: Faster, cheaper and most effective in lung cancer staging. *Int J ClinPract.* 2018;72(2): 10.1111/ijcp. 13053.
10. Gahlot T, Parakh U, Verma K, Bhalotra B, Jain N. Endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing mediastinal lymphadenopathy. *Lung India* 2017;34:241-6.
11. Dhamija A, Basu A, Sharma V. Mediastinal adenopathy in India: Through the eyes of endobronchial ultrasound. *J Assoc Physicians India* 2015;63:15-8.

12. Srinivasan A, Agarwal R, Gupta N, Aggarwal AN, Gupta D. Initial experience with real time endobronchial ultrasound guided transbronchial needle aspiration from a tertiary care hospital in north India. *Indian J Med Res* 2013;137:803-7.
13. Madan K, Mohan A, Ayub II, Jain D, Hadda V, Khilnani GC, Guleria R. Initial experience with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from a tuberculosis endemic population. *J BronchologyIntervPulmonol*. 2014 Jul;21(3):208-14.
14. Herth FJ, Eberhardt R, Vilmann P, Krasnik M, Ernst A. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. *Thorax*. 2006 Sep;61(9):795-8.
15. YilmazDemirci N, Öztürk C. Diagnostic utility of endobronchial ultrasound-guided transbronchial needle aspiration in elderly patients. *TuberKToraks*. 2018 Jun;66(2):115-121.
16. Madan K, Dhungana A, Mohan A, Hadda V, Jain D, Arava S, Pandey RM, Khilnani GC, Guleria R. Conventional Transbronchial Needle Aspiration Versus Endobronchial Ultrasound-guided Transbronchial Needle Aspiration, With or Without Rapid On-Site Evaluation, for the Diagnosis of Sarcoidosis: A Randomized Controlled Trial. *J BronchologyIntervPulmonol*. 2017 Jan;24(1):48-58.
17. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, Tomassetti S, Nanni O, Poletti V. EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *ClinRespir J*. 2012 Jan;6(1):3-8.

Case Report

Pulmonary Adenocarcinoma Masquerading as ILD

Akhilesh Kunoor¹, Balasubramoniam K.R.², Deepu M.³, Sreeraj Nair ⁴, P. T. James⁵

- 1) Associate Professor, Department of Pulmonary Medicine
2) Associate Professor, Department of Cardiovascular and Thoracic Surgeries, 4) Junior Resident, 5) Professor and HOD, Department of Pulmonary Medicine, Amrita Institute of Medical Science, Kochi, Kerala, India
3) Consultant Pulmonologist, Department of Pulmonary Medicine, Caritas Hospital, Kottayam, Kerala, India

Abstract

Pulmonary adenocarcinoma presents in different ways clinically and radiologically. Primary lung cancer presenting as Interstitial Lung disease (ILD) is very rare. Our case presented with manifestation of interstitial lung disease and was initially treated with steroids. Due to non-resolution of clinical symptoms as well as radiological worsening, we went ahead with VATS lung biopsy and the case was finally proved as adenocarcinoma which was confirmed by immunohistochemistry. This case proves that timely referral for lung biopsy is required in selected cases of interstitial lung disease when it is not responding to conventional treatment

Key words

Adenocarcinoma, ILD, VATS lung biopsy

Key Messages

Timely referral for lung biopsy is needed in case of clinicoradiologically persisting or worsening interstitial pattern even with optimal treatment.

Introduction

Pulmonary adenocarcinoma is unique in clinical, radiological and pathological presentations. Association of lung cancer in interstitial lung disease (ILD) is widely reported. But primary lung cancer presenting as interstitial lung disease (ILD) is a rare entity and not widely reported from India. Here we

describe a case of primary lung cancer which presented as interstitial lung disease (ILD).

Case History

A 47 year old farmer, reformed smoker, who had significant history of exposure to poultry and pesticides presented to a local hospital with a 4 month

history of non-productive cough and progressive breathlessness. There was no history of fever, hemoptysis, weight loss or joint pain. There were no comorbidities like hypertension, diabetes, COPD or asthma. He was evaluated with routine blood investigations and chest X-ray. Initial chest X-ray (Figure 1) showed bilateral reticulonodular opacities with mid and lower zone predominance with no significant volume loss.



Fig. 1: Chest Xray showing bilateral reticulonodular opacities with mid and lower zone predominance.

He was further evaluated with CT thorax (Figure 2) which showed bilateral nodular shadows with random and peri-bronchial distribution, associated fibrotic changes in bilateral lungs with traction dilatation of bronchi and mediastinal lymphadenopathy [Largest measuring 13 X 10 mm].




Fig. 2: CT Thorax showing reticulonodular opacities with peribronchovascular distribution associated with traction bronchiectasis

He was evaluated with spirometry which showed restrictive pattern, however DLCO was 70% predicted. Bronchoscopy was done in the previous centre and BAL AFB smear, Genexpert and cytology were normal. He was started on prednisolone 30 mg once daily on suspicion of subacute hypersensitivity pneumonitis. But as there was no clinico-radiological improvement patient was referred to our centre. When he presented to our hospital, he was afebrile, his vitals were stable and there was bilateral rhonchi on chest auscultation.

He was further evaluated in our centre. His total WBC count was 6300 and CRP was 66 mg/L. Mantoux test was non-reactive. Serum calcium, ANA screening, ANA profile, anti CCP antibody were all normal. Serum ACE was 79 IU/ml. Chest X-ray was repeated from our centre which depicted bilateral reticulonodular opacities with mid and lower zone predominance.

Spirometry showed a restrictive pattern. He could perform a walk distance of 300 meters with no desaturation in six minutes walk test. As there was no clinico-radiological improvement the patient underwent VATS biopsy. Biopsies were taken from visceral pleural nodule and nodule from the right middle lobe. (Figure 3)



Fig. 3: Middle lobe wedge biopsy of visceral pleural nodule using Endostapler via VATS

On histopathological examination it was diagnosed as invasive mucinous adenocarcinoma with tumour infiltration. (Figure 4). Immunohistochemistry examination was positive for CK7, CEA and negative for CK20 (Figure 5) confirming it as primary lung malignancy.




Fig. 4 : Histopathology examination showing invasive mucinous adenocarcinoma with tumor infiltration




Fig. 5 : Cells are positive for CK7, CEA and negative for CK20.

Discussion

Association of lung cancer in established ILD is well documented. There are reports of higher prevalence of lung cancer in the IPF population, varying from 4.8%-48%¹. Primary lung cancer presenting as interstitial lung disease is rare. In this case clinico radiologically the features were suggestive of an interstitial pathology.

Pulmonary adenocarcinoma is unique in clinical presentation, epidemiology and radiology. It arises from type 2 pneumocytes. The WHO defines bronchoalveolar

carcinoma as a subtype of adenocarcinoma with growth along the alveolar septa and without evidence of stromal, vascular or pleural invasion. Histologically there are three types- mucinous, non mucinous, mixed². The usual clinical presentations are cough, breathlessness and bronchorrhea. Adenocarcinoma has been described previously with presentations like non resolving pneumonia⁴. Though there are diverse presentations, rarely adenocarcinoma can present with interstitial involvement. Very few case reports of similar conditions are available^{3,5}. The exact pathogenesis of interstitial shadowing is not known. Most probably intense inflammation and fibrosis may overshadow tumour proliferation and masquerade as ILD³.

In this case, clinico radiological and functional evaluation was suggestive of early onset of interstitial lung disease more likely hypersensitivity pneumonitis and the patient was started on oral corticosteroids. Since the response to treatment was poor, we proceeded with surgical lung biopsy which is the gold standard for diagnosing ILD. Surgical lung biopsy being invasive is not preferred usually, but now can be done safely with video assisted thoracoscopic method. In a study by Kayatta et al, surgical lung biopsy provided 88% accurate specific diagnosis of ILD in comparison with 15% without a surgical lung biopsy⁶. VATS biopsy is a very safe procedure with mortality rate of 0-2% in low risk patients and 0-11% in patients whose risk was not stratified⁶. So all cases of ILD which has a poor response to steroids or has an atypical presentation would warrant a lung biopsy.

Conclusion

Adenocarcinoma especially bronchoalveolar carcinoma has diverse presentations. It should also be included in differential diagnosis of interstitial lung disease. So all ILD which respond poorly to treatment should be evaluated for alternate diagnosis and this should include bronchoscopic or surgical lung biopsy for obtaining a tissue diagnosis.

References

1. Guler S, Berezowska S, Christie A, Funke M, Geiser T. When Malignancies Mimic Interstitial Lung Disease: A Case Series and Review of the Literature. *J Clin Respir Dis Care* 2015;1:104.

- 2) W. D. Travis, K. Garg, and K. Garg, "Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma," *Journal of Clinical Oncology*, vol. 23, no. 14, pp. 3279–3287, 2005.
- 3) S. Lantuejoul, T.V. Colby , G.R. Ferretti , P.Y. Brichon}, C. Brambillaz, E. Brambilla. Adenocarcinoma of the lung mimicking inflammatory lung disease with honeycombing. *Eur Respir J* 2004; 24: 502–505
- 4) Thompson WH, Bronchioloalveolar carcinoma masquerading as pneumonia. *Respiratory care*, 2004 49: 1349-1353.
- 5) Raparia K, Ketterer J, Dalurzo ML, Chang YH, Colby TV, et al. Lung tumors masquerading as desquamative interstitial pneumonia (DIP): report of 7 cases and review of the literature. *Am J Surg Pathol*, 2014, 38: 921-924.
- 6) Kayatta O.M,Ahmed Shair,Hammel A Josh,Fernadz Felix,Picens Alen etal. Surgical Biopsy of Suspected Interstitial Lung Disease Is Superior to Radiographic Diagnosis.*Ann Thorac Surg* 2013;96:399–402.

Case Report

Intralobar Sequestration - A Case Report

Jayaprakash B.* Reshmi S. Nair** Bismil Aisha Basheer***

*Additional Professor, **Associate Professor, ***Junior Resident
Department of Pulmonary Medicine
Govt. Medical College, Trivandrum, Kerala.

Abstract

Intralobar pulmonary sequestration(ILS) is characterized by the presence of nonfunctional parenchymal lung tissue, receiving systemic arterial blood supply. It lacks normal communication with tracheobronchial tree. Most of the ILSs are located in the posterior basal segments of the left lung. Patients with ILS are either asymptomatic or they present with recurrent respiratory infection or hemoptysis. Failure to diagnose and treat this condition can lead to recurrent pneumonia and fatal hemoptysis. A case of recurrent respiratory infection for 20 yrs was investigated and diagnosed as Intralobar sequestration, and is reported due its rarity.

Key Words

Pulmonary sequestration, intralobar, case report.

Introduction

Pulmonary sequestration is a mass of abnormal pulmonary tissue that does not communicate with the tracheobronchial tree and is supplied by an anomalous systemic artery. Bronchopulmonary sequestration is a benign, rare lung abnormality and anatomically it is classified into intralobar and extralobar sequestration. ILS is more common on the left lower lobe. We present a case of ILS on the right lower lobe due to its rarity.

Case Report

35 year old male from Trivandrum district was admitted to Department of Pulmonary Medicine, Medical college, Trivandrum with complaints of fever and cough of two weeks duration. Cough was productive with yellowish sputum that was foul-smelling initially. No postural variation or blood staining was noticed for expectoration. Fever was high grade with chills and rigor, which subsided with medication. There was no history of seizures or loss of consciousness. He did not give history of breathlessness, wheeze, chest pain, loss of

appetite or weight. He gave history of recurrent episodes of cough with purulent expectoration for last 20 years. He gave history of hospital admission 20 years back for Pneumonia. No past history of hemoptysis. For the present episode he had a course of antibiotics from local hospital and was referred to us in view of the persistence of chest x-ray lesion.

The patient did not give history of anti tuberculosis treatment in the past. He is not a known diabetic or hypertensive. He did not give history of episodic breathlessness, wheeze or atopic symptoms. There was no history of recurrent sinusitis or ear infections. Sleep and appetite were normal. There was no change in bowel or bladder habits. He was not a smoker but had passive smoking exposure from co-workers. He was an occasional alcoholic, but did not give history of binge drinking or alcoholic blackouts. No other addictions. No history of exposure to pets. He did tile fixing works for around 15 years. No history of respiratory distress following birth. He was adequately immunized. He was married and had two children.

On examination he was conscious and oriented, moderately built and nourished, He had a BMI of 25.7. General examination revealed grade 1 clubbing. His vitals were stable at the time of examination. There was no pallor, icterus, cyanosis, lymphadenopathy or pedal edema. Pulse rate was 94/min, regular, normal volume and character, no radio femoral or radio radial delay. All peripheral pulses palpable. His Blood Pressure was 110/ 70 mmHg in right upper limb in sitting position, Respiratory rate was 22/min, SpO2 - 99% room air and temperature was normal. His respiratory system examination was normal except for coarse crepitations which were heard in the right infra axillary, infra scapular and lower inter scapular region. The other systems were normal on examination.

His routine blood examination showed Hb 14.2g/dl,TC of 5400 with 62% neutrophils and 45 mm/hr. His blood sugar, LFT and RFT were normal. Sputum AFB smear examination was negative and sputum culture and sensitivity showed normal pharyngeal flora. His viral markers were non reactive.

Chest x-ray showed multiple cystic shadows in the right lower zone (fig 1). HRCT Thorax showed heterogenous attenuation of lung noted in posterior

basal segment of right lower lobe with multiple cystic areas and air fluid levels. No obvious communication is demonstrable with right lower lobe bronchus or its segmental branches (fig 2). Contrast study shows systemic arterial supply to the lesion from below diaphragm via a branch from Coeliac trunk. Venous drainage is via pulmonary vein (right inferior). No separate pleural lining identified for the abnormal lung parenchyma. Mediastinal windows revealed subcentimetric prevascular and lower paratracheal



Fig. 1 : Chest x-ray showing multiple cystic shadows with fluid levels in the right lower lobe




Fig. 2 : Heterogenous attenuation of lung in posterior basal segment of right lower lobe with multiple cystic areas and air fluid levels




Fig. 3 : Image showing arterial blood supply to sequestered lung from celiac trunk.

lymph nodes. CECT Chest /aortography showed infected intralobar sequestration in right lower lobe of lung with arterial supply from coeliac trunk and venous drainage into right inferior pulmonary vein (fig 3). A confident diagnosis of Intralobar sequestration was made and the patient was referred to cardiothoracic surgery for right lower lobectomy in view of his recurrent respiratory infections. Right lower lobectomy was done after careful identification and ligation of the feeding vessels. Post operative period was uneventful and the patient remains asymptomatic on follow up.

Discussion

Pulmonary sequestration is a relatively rare entity comprising 0.15-6.4% of all congenital pulmonary malformations⁽¹⁾. Pulmonary sequestration was first described by Rektorzik in 1861, as a malformation comprised of dysplastic lung tissue with no normal communication with the tracheobronchial tree and with an anomalous systemic arterial supply⁽²⁾. There are two types of pulmonary sequestrations: Intralobar sequestration (ILS), which is surrounded by normal lung tissue; and extralobar sequestration (ELS), which has its own pleural investment. Intrapulmonary sequestration is four times more common than the extralobar type. Sequestrations develop because of accessory primordial lung buds, which may be invested with in normal lung tissue in intralobar or external to the normal lungs in extralobar sequestration⁽³⁾.

Patients can present with an incidental

pulmonary lesion on imaging and be otherwise asymptomatic. More commonly however, they may manifest varying degrees of pulmonary symptomatology such as pleural effusions or recurrent pneumonia⁽⁴⁾. Intralobar sequestration usually presents in the adolescent age. The most common site for intralobar sequestration is posterior basal segment of left lower lobe. The arterial supply is variable with 74% being supplied by the thoracic aorta, while the remainder originates from the abdominal aorta and its branches including the gastric or splenic arteries. Typically, venous drainage from these lung segments is via the pulmonary venous system, although systemic drainage has been noted as well⁽⁵⁾. Savic B and colleagues in their analysis found that, the aberrant artery in intralobar sequestration originated in 74% of all cases from the thoracic aorta, and in 14.8% there was more than one anomalous artery. The mean diameter of the aberrant arteries was 6.3-6.6 mm⁽¹⁾. Many theories have been suggested to elucidate the embryologic mechanism responsible for sequestrations. During lung development, an insult to the developing pulmonary arterial blood supply occurs leading to retention and proliferation of the nascent systemic capillary network. Achieving a diagnosis of pulmonary sequestration can range in difficulty depending upon the type of anomaly and presenting symptoms. Computed tomography will typically suffice in most adult cases with the need for angiography to demonstrate blood supply⁽⁶⁾. It is important to differentiate sequestration from other congenital malformations specifically, cystic adenomatoid malformation and scimitar syndrome. Definitive treatment involves resection of the affected lung segment. Accurate preoperative identification of the arterial blood supply is crucial since inadvertent injury of these systemic vessels can have a fatal consequence. Endovascular treatment of pulmonary sequestration, with selective embolization of the inflow arteries, is a very attractive minimally invasive therapeutic option, as compared with conventional surgery, and potentially less prone to associated complications⁽⁷⁾. Resection via minimal-access procedures such as VATS lobectomy is another option thereby permitting early discharge and a low rate of complications⁽⁸⁾. Pulmonary sequestration is a rare entity especially in the adult population and early surgical resection should continue to be the standard of care in both adolescent and adult patients with this disease process. Although intralobar sequestration is more

common on left side, our patient had right sided sequestration. His surgery and postoperative period were uneventful. He was totally asymptomatic on follow up.

References

1. Savic B, Bertel FJ, Tholen W, et al. Lung sequestration: report of seven cases and review of 540 published cases. *Thorax* 1979; 34:96-101
2. Felker RE, Tankin IL. Imaging of pulmonary sequestration. *AJR Am J Roentgenol.* 1990; 154:241-9
3. Murray and Nodel's Text book of Respiratory Medicine. Sixth Edition. Elsevier. 865
4. Hertenberg C, Daon E, Kramer J. Intralobar pulmonary sequestration in adults: three case reports. *Journal of Thoracic Disease.* 2012;4(5):516-519.
5. Sellke F, Townsend C Jr, Beauchamp R, et al. Sabiston and Spencer's surgery of the chest, eighth edition 2010.
6. Clements BS, Warner JO. Pulmonary sequestration and related congenital bronchopulmonary-vascular malformations: nomenclature and classification based on anatomical and embryological considerations. *Thorax* 1987; 42:401-8.
7. Marine LM, Valdes FE, Mertens RM, et al. Endovascular treatment of symptomatic pulmonary sequestration. *Ann Vasc surg* 2011;25:696.e11-5.
8. Gonzalez D, Garcia J, Fieira E, et al. Video-assisted thoracoscopic lobectomy in the treatment of intralobar pulmonary sequestration. *Interact Cardiovasc Thorac Surg* 2011; 12:77-9.

Case Report

Intrapulmonary Teratoma - Bronchoscopic Visualisation

Kesavan Nair V.*, Rahul Ramachandran**

*Professor and Senior Consultant, **Resident
Dept. of Respiratory Medicine
KIMS, Thiruvananthapuram - 29

Corresponding Author : V. Kesavan Nair

Abstract

Mediastinal teratomas are among the third common type of teratomas after ovary and testes. Primary or Intrapulmonary teratomas are extremely rare and it is said that intra pulmonary teratomas are one of the rarest tumours encountered by pathologists (Spencer)¹. The diagnosis is usually made after surgery. A pre operative diagnosis by bronchoscopy is extremely rare². We report this case where the diagnosis was established pre operatively by bronchoscopic visualisation of hairs in the bronchus.

Key Words

Bronchoscopy, Intrapulmonary, teratoma, visualisation.

Case Report

A 22 year old girl presented to the Department of Respiratory Medicine with a chronic cough with mucoid and at times purulent expectoration since childhood. She also had occasional haemoptysis. She had 2 courses of anti tuberculous drugs three years apart as the treating doctors suspected tuberculosis from her X rays. Her sputum was never positive for AFB and she was told that her X rays had not cleared even after complete course of the drugs. Drug resistance was suspected and she was referred.

Examination showed a moderately built and

well nourished young girl who was coughing off and on but was not dyspnoeic. She was afebrile, had no clubbing or lymphadenopathy. Respiratory system examination revealed diminished breath sounds on the left side, dull percussion, bilateral wheezes and crackles predominantly on the left side.

Blood investigations showed polymorpho nuclear leucocytosis, ESR of 80mm/hr, polycythemia with Hb of 18 gm%, and normal hepatic and renal function. The Chest x ray showed opacification of the left lung with the presence of irregular calcifications near the centre of the opacity. As the diagnosis was not definite, bronchoscopy was planned.




Fig. 1 : Bronchoscopic photograph showing single and tuft of hairs (arrows)

Fibre-optic bronchoscopy was done under local anaesthesia. During the procedure, the girl had cough in spite of adequate amount of local anaesthetic and pre medication. The vocal cords could be negotiated fairly easily but the carina and the bronchial tree on the right side had chronic inflammatory changes with ulcerations and sloughing. The left main bronchus looked black with hairs 'waving' in the air flowing through. Pus exuded from the distal end and the bronchoscope could not be moved into the left main bronchus. The patient had immediate relief after suctioning out pus. The visualisation of hairs through the bronchoscope made it possible to diagnose 'intra-pulmonary teratoma'. The pus did not show AFB, culture was negative and there were no malignant cells.



Fig. 2 : Cut section of left lung - post pneumonectomy showing hairs & skeletal tissue

The patient had very good symptomatic improvement after bronchoscopy. After making a diagnosis of intrapulmonary teratoma, she was referred to thoracic surgeon. She underwent left pneumonectomy. Post procedure patient was asymptomatic.

The histopathological examination of the resected specimen showed the mass to be well encapsulated with the presence of hair, teeth, bone etc.




Fig. 3 : Histopathology specimen showing different types of tissues in Teratoma.

Discussion

Intrapulmonary teratomas are rare; only 44 cases have been reported in the world literature till 2007.⁷ These tumors are thought to originate from the third pharyngeal pouch. They occur equally in men and women and usually are diagnosed in the second to fourth decade of life. They are more often benign than malignant. Malignant lesions have a better post operative prognosis. Benign lesions may exhibit high morbidity and mortality because of their size and location⁸. These tumors present radiographically as lobulated masses that may contain calcification or peripheral collections of air. They most often occur in the upper lobes.

There are very few case reports of bronchoscopic visualisation of the intrapulmonary teratoma pre operatively in world literature. M.Y. Ali and P.K. Wong¹ reviewed 15 cases of intrapulmonary teratoma in Thorax in 1964. Most of these cases were diagnosed post operatively as bronchoscopy was not common place. Again in 1983 a case of recurrent

teratoma, initially mediastinal and later intrapulmonary, was reported by Präuer et al² from Munich. The intrapulmonary teratoma in this case was seen through the bronchoscope as a tuft of hair. From India, Dr. Sushama et al⁵ from Calicut, Kerala, South India reported a case in which whitish material could be seen coming out from the involved bronchus during bronchoscopy. Our case is unique in that the diagnosis could be established by bronchoscopic visualisation of hairs in the bronchi and the presence of a mass with calcifications inside. But the patient never had trichoptysis which is mentioned in many cases. A similar case is reported in a male patient where pre operative diagnosis was made.⁹ A high index of suspicion is required in such cases especially when there are calcific spots inside the mass. CT thorax will be helpful for a pre operative diagnosis in most of the cases. Because of its potential for rupture or malignancy, surgical removal is the curative treatment.

References

1. Ali MY, Wong PK. Intrapulmonary Teratoma. *Thorax*. 1964;19(3):228-35.
2. Präuer HW, Mack D, Babic R. Intrapulmonary teratoma 10 years after removal of a mediastinal teratoma in a young man. *Thorax*. 1983;38(8):632-4.
3. Morgan DE, Sanders C, McElvein RB, Nath H, Alexander CB. Intrapulmonary teratoma: a case report and review of the literature. *J Thorac Imaging*. 1992 Jun;7(3):70-7.
4. Asano S, Hoshikawa Y, Yamane Y, Ikeda M, Wakasa H. An intrapulmonary teratoma associated with bronchiectasia containing various kinds of primordium: a case report and review of the literature. *Virchows Arch*. 2000 Apr;436(4):384-8.
5. Sushama A, Gomathy S, Rajendran V R, Vasu C K. Mature intrapulmonary teratoma - a case report. *Indian J Radiol Imaging* 2003;13:31-2.
6. Khan J, Aslam F, Fatimi S, Ahmed R. Cough, fever and a cavitary lung lesion-An intrapulmonary teratoma. *Journal of Postgraduate Medicine* 2005; 51: 330-1.
7. Agarwal R, Srinivas R, Saxena AK. Trichoptysis due to an intrapulmonary teratoma. *Respir Care*. 2007; 52 (12):1779–1781.
8. Rana SS, Swami N, Mehta S, Singh J, Biswal S. Intrapulmonary teratoma: an exceptional disease. *Ann Thorac Surg*. 2007;83(3):1194–1196.
9. Cai C, Zeng Y, Chen H, Gu Y, Zeng Q, Zhong N. Fibrobronchoscopic evidence of endobronchial hairs in intrapulmonary teratoma with hemoptysis but without trichoptysis. *Am J Med Sci*. 2008;336(5):441–444.
10. Mondal SK, Dasgupta S. Mature cystic teratoma of the lung. *Singapore Med J* 2012; 53(11): e237–e239.

GUIDELINES FOR AUTHORS

The merit of the publication lies in its quality and content. Contributions are invited on any aspect of Pulmonary and critical care medicine. Articles are accepted on the basis of significance, scientific perfection and practical applicability. Authors are requested to base their papers on the basis of original work carried out by themselves or their groups. Manuscripts should not be submitted to more than one journal at a time.

All articles are subjected to a peer review process. Each article is assessed blindly by one or more referees depending on the manuscript type and comments sent back to the authors for revision as required. The Editor's decision is final on accepting or rejecting an article.

The types of articles published in the journal are as follows

1. Editorials
2. Reports of original research
3. Critical reviews
4. Meta analysis
5. Case reports (series) with discussions
6. Radiology pearls
7. Educational forum
8. Letters to editor

Manuscripts should be submitted by e-mail or CD in MS Word addressed to,

Dr. Suraj K.P.
The Editor-in-Chief, Pulmon,
Professor, Dept. of Pulmonary Medicine,
Govt. Medical College, Kozhikode, Kerala, 673008.
Ph. 9447445135
E mail: drsurajkp@yahoo.com

Requirements for submission of manuscript

Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see *Ann Intern Med* 1997;126:36-47).

The manuscript should be accompanied by

1. Covering letter
2. Undertaking by authors
3. Copyright transfer agreement form.

Covering Letter

The covering letter should explain why the paper should be published in the Pulmon. One of the authors could be identified as the corresponding author of the paper, who will bear the responsibility of the contents of the paper. The name, address, and telephone number of the corresponding author should be provided for all future communication related with the publication of the article. The letter should give any additional information that may be helpful to the editor, such as the type of article and whether the author(s) would be willing to meet the

cost of reproducing color illustrations.

Undertaking by Author(s)

It is necessary that all the authors give an undertaking (in the format specified by the journal) indicating their consent to be co-authors in the sequence indicated on the title page. Each author should give his or her names as well as the address and designation current at the time the work was done, plus a current address for correspondence including telephone and fax numbers and email address. A senior author may sign the Undertaking by Authors for a junior author who has left the institution and whose whereabouts are not known and take the responsibility. (Format for submission of undertaking is provided at the end of the session.)

Copyright Transfer Agreement

Author(s) will be asked to sign a transfer of copyright agreement, which recognizes the common interest that both journal and author(s) have in the protection of copyright. It will also allow us to tackle copyright infringements ourselves without having to go back to authors each time. (Format for submission of copyright is provided at the end of the session.)

Manuscript

Manuscripts should be presented in as concise a form as possible, typewritten in double space and numbered consecutively. The contents should be arranged in the following order:

Title page, Abstract, Key words, Introduction, Material & Methods, Results, Discussion, Summary, Acknowledgement and References. Abstract, Tables and legends for Figures should be typed on separate sheets and not in continuation of the main text. *Figures and Photographs should be presented in JPEG or GIF format.*

Title Page

The title page should carry 1) the title of the article, 2) the name by which each author is known, with his or her highest academic degree and institutional affiliation, 3) the name of the department(s) and institution(s) to which the work should be attributed; 4) disclaimers, if any; 5) the name and address of the author responsible for correspondence and to whom requests for reprints should be addressed; 6) source(s) of support in the form of grants, equipment, drugs, or all of these.

Title of the article should be short, continuous (broken or hyphenated titles are *not* acceptable) and yet sufficiently descriptive and informative so as to be useful in indexing and information retrieval. A short running title not

exceeding 6-7 words to be provided at the foot of the title page.

Abstract

All manuscripts should have a structured abstract (not more than 250 words) with subheadings of Background

& objectives, Methods, Results, Interpretation and Conclusions. Abstract should be brief and indicate the scope and significant results of the paper. It should only highlight the principal findings and conclusions so that it can be used by abstracting services without modification. Conclusions and recommendations not found in the text of the articles should not be inserted in the abstract. A set of suitable key words arranged alphabetically may be provided.

Introduction

Introduction should be brief and state precisely the scope of the paper. Review of the literature should be restricted to reasons for undertaking the present study and provide only the most essential background.

Material & Methods

The procedures adopted should be explicitly stated to enable other workers to reproduce the results, if necessary. New methods may be described in sufficient detail and indicating their limitations. While reporting experiments on human subjects and animals, it should be clearly mentioned that procedures followed are in accordance with the ethical standards laid down by the national bodies or organizations of the particular country. Scanned certificate of ethical clearance should be provided along with manuscript manuscripts in relevant context. The drugs and chemicals used should be precisely identified, including generic name(s), dosage(s) and route(s) of administration.

The statistical analysis done and statistical significance of the findings when appropriate should be mentioned. Unless absolutely necessary for a clear understanding of the article, detailed description of statistical treatment may be avoided.

Results

Only such data as are essential for understanding the discussion and main conclusions emerging from the study should be included. The data should be arranged in unified and coherent sequence so that the report develops clearly and logically. Data presented in tables and figures should *not* be repeated in the text. Only important observations need to be emphasized or summarised. The same data should not be presented both in tabular and graphic forms. Interpretation of the data should be taken up only under the Discussion and *not* under Results.

Discussion

The discussion should deal with the interpretation of results without repeating information already presented under Results. It should relate new findings to the known ones and include logical deductions. It should also mention any weaknesses of the study.

Summary and conclusions

The summary should provide a brief account of most the relevant observations and conclusions based on the observed data only. This should be linked with the objectives of the study. Statements and conclusions not supported

by the data should be avoided. Claims of ongoing studies should also be avoided.

Acknowledgment

Acknowledgment should be brief and made for specific scientific/technical assistance and financial support only and *not* for providing routine departmental facilities and encouragement or for help in the preparation of the manuscripts (including typing or secretarial assistance).

References

References should be typed on separate page after the text. The total number of References should normally be restricted to a maximum of 30. They should be numbered consecutively in the order in which they are first mentioned in the text. In the text they should be indicated above the line (superior). As far as possible avoid mentioning names of author(s) in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses. References cited only in tables or figure or legends should be numbered in accordance with the sequence in which they appear in the manuscript.

Style of citing references

Use the style of the examples below. The titles of journals should be abbreviated according to the style used in Index Medicus. Avoid using abstracts as references. References of papers accepted but not yet published should be designated as ? in press or ? forthcoming. Authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should be cited in the text as ? unpublished observations with written permission from the source.

Avoid citing a personal communication, unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, authors should obtain written permission and confirmation of accuracy from the source of a personal communication. Please refer <http://www.icmje.org> for further details.

All references must be verified by the author(s) against the original documents.

1. Standard Journal article

List the first six authors followed by et al. The usual style is surname followed by initials as shown below

Vega KJ, Pina I, Krevsky B. Heart transplantation is associated with an increased risk for pancreatobiliary disease. *Ann Intern Med* 1996; 124:980-3.

2. Organization as author

The Cardiac Society of Australia and New Zealand. Clinical exercise stress testing. Safety and performance guidelines. *Med J Aust* 1996; 124:282-4.

3. Books and other Monographs

Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.

4. *Editor(s), compiler(s) as author*

Norman IJ, Redfern SJ. editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996.

5. *Chapter in a book*

Philips SJ, Whisnant JP Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press;1995.p.465-78.

6. *Unpublished Material In press*

Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. In Press 1996.

7. *Journal article in electronic format*

Morse SS. Factors in the emergence of infectious diseases. Emerge Infect Dis [serial online] 1995 Jan-Mar (cited 1996 Jun 5); 1 (1): [24 screens]. Available from: URL: <http://www.cdc.gov/ncidod/EID/eid.htm>.

Tables

Type each table with double spacing on a separate sheet of paper. Do not submit tables as photographs. Number the tables consecutively (in Arabic numerals) in the order of their first citation in the text and supply a brief title for each. Give each column a short or abbreviated heading. Place explanatory matter as footnotes, and not in the heading. For footnotes use the following symbols, in this sequence: *, †, ~, §, ¶, ~, **, tt, ~. Explain in footnotes all abbreviations that are used in each table.

Illustrations (Figures)

Figures should be either professionally drawn and photographed, or submitted as photographic-quality digital prints. For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 x 173 mm (5 x 7 inches).

Letters, numbers, and symbols on figures should be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Photomicrographs should have internal scale markers.

Symbols, arrows, or letters used in photomicrographs should contrast with the background.

Figures should be numbered consecutively according to the order in which they have been cited in the text. Titles and explanations should be provided in the legends not on the illustrations themselves. **Each figure should have**

a label pasted on its back indicating the number of the figure and the running title. Do not write on the back of figures, scratch, or mark them by using paper clips.

Legends for Illustrations (Figures)

Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When **symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs.**

If a **figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce the figure.** Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.

Color printing requires additional cost that will be communicated to the author.

An electronic version of the figures in JPEG or GIF should be provided for web version. The authors should review the images of such files on a computer screen before submitting them to be sure they meet their own quality standards.

Units of Measurements

Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Temperatures should be given in degrees Celsius. Blood pressures should be given in millimeters of mercury. All hematologic and clinical chemistry measurements should be reported in the metric system in terms of the International System of Units (SI). Editors may request that alternative or non-SI units be added by the authors before publication.

Abbreviations and Symbols

Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should **precede its first use in the text unless it is a standard unit of measurements.**

Proofs and reprints

Authors of accepted articles are supplied printer's proofs either by post or through e-mail. Corrections on the proof should be restricted to printer's errors only and no substantial additions/deletions should be made. **No change in the names of the authors** is permissible at the proof stage. Reprints up to 10 would be supplied as per request of the corresponding author.

UNDERTAKING BY AUTHORS

We, the undersigned, give an undertaking to the following effect with regard to our article entitled ".....
....." submitted for publication in Pulmon, the journal of Respiratory Sciences.

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will *not* be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study *i.e.*, (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge the journal's **conflict of interest** policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence)	Signature of Authors
1.
2.
3.
4.
5.
6.
7.
8.

Copyright Transfer Agreement Form

This document must be signed by all authors and submitted with the manuscript.

COPYRIGHT TRANSFER AGREEMENT

Pulmon, the Journal of Respiratory Sciences is published in 3 issues a year by the Academy of Pulmonary and Critical Care Medicine.

The Pulmon and Authors hereby agree as follows: In consideration of Pulmon reviewing and editing the following described work for first publication on an exclusive basis:

Title of manuscript:

The undersigned author(s) hereby assigns, conveys, and otherwise transfers all rights, title, interest, and copyright ownership of said work for publication. Work includes the material submitted for publication and any other related material submitted to Pulmon. In the event that Pulmon does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).

The assignment of rights to Pulmon includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof.

All accepted works become the property of Pulmon and may not be published elsewhere without prior written permission from Pulmon. The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.

Authors' Names (in sequence)	Signature of Authors
1.
2.
3.
4.
5.
6.
7.
8.